Cargando...

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: van Luijn, Johan C F, Gribnau, Frank W J, Leufkens, Hubert G M
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Science Inc 2007
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/
https://ncbi.nlm.nih.gov/pubmed/17166187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!